Galderma Announces Top-Line Results of Clinical Study Showing Patients Treated with Dysport® (abobotulinumtoxinA) Achieved High Levels of Satisfaction and Natural-Looking Results with Two Treatments Per Year
- Tuesday, May 12, 2020, 7:03
- Finance
- Add a comment
LAUSANNE, Switzerland, May 12, 2020 /PRNewswire/ — Galderma today announced results of DREAM (Dysport Real-world Evaluation and Measured satisfaction study), a clinical study of Dysport®* (abobotulinumtoxinA) for Injection that evaluated patient satisfaction and safety with a…
About the Author
adminasapcorp has written 41555 stories on this site.